Trial Profile

A Phase II trial of T-2307 for cryptococcal meningitis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATI 2307 (Primary)
Indications Cryptococcal meningitis
Focus Therapeutic Use
Sponsors Appili Therapeutics

Most Recent Events

10 Nov 2022 According to Appili Therapeutics media release, the company plans to focus its resources on advancing its portfolio of infectious disease and biodefense assets, including ATI-1701, ATI-1801, and ATI-1501 and will discontinue development of ATI-2307.
24 Jun 2021 According to Appili Therapeutics media release, it plans to file a Phase 2 protocol with regulatory agencies by the end of this year and it plans to start Phase 2 clinical trials in 2022.
27 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com